Abstract
In this article we produce present practice in treatment of advanced stages of non-small cell lung cancer with activating mutations in EGFR genes. Describe opportunities of effective using of target agents in these cases. There are notions about mechanisms of resistance for target therapy, and demonstrate different approach in this field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
